Blockade of the complement C5a receptor reduces incisional allodynia, edema, and cytokine expression

Anesthesiology

Volumn 104, Issue 6, 2006, Pages 1274-1282

  Clark, J David ^a,b   Qiao, Yanli ^a   Li, Xiangqi ^a   Shi, Xiaoyou ^a   Angst, Martin S ^a   Yeomans, David C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT COMPONENT C5A RECEPTOR INHIBITOR; CYCLOPEPTIDE; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG SELECTIVITY; EDEMA; HINDLIMB; INCISION; INFLAMMATION; MALE; MOUSE; NONHUMAN; PAIN THRESHOLD; PAW EDEMA; PRIORITY JOURNAL; SKIN; STATISTICAL SIGNIFICANCE;

ANIMALS; COMPLEMENT C5A; CYTOKINES; EDEMA; LEUKOCYTES; MALE; MICE; MICE, INBRED C57BL; PAIN; PEPTIDES, CYCLIC; RNA, MESSENGER;

EID: 33744963014     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/00000542-200606000-00024     Document Type: Article

References (61)

1. Molina H: Complement and immunity. Rheum Dis Clin North Am 2004; 30:1-18, v
2. Mastellos D, Germenis AE, Lambris JD: Complement: an inflammatory pathway fulfilling multiple roles at the interface of innate immunity and development. Curr Drug Targets Inflamm Allergy 2005; 4:125-7
3. Mastellos D, Andronis C, Persidis A, Lambris JD: Novel biological networks modulated by complement. Clin Immunol 2005; 115:225-35
4. Andersson I, Tylman M, Bengtson JP, Bengtsson A: Complement split products and pro-inflammatory cytokines in salvaged blood after hip and knee arthroplasty. Can J Anaesth 2001; 48:251-5
5. Bryan D, Walker KB, Ferguson M, Thorpe R: Cytokine gene expression in a murine wound healing model. Cytokine 2005; 31:429-38
6. Sato Y, Ohshima T: The expression of mRNA of proinflammatory cytokines during skin wound healing in mice: A preliminary study for forensic wound age estimation (II). Int J Legal Med 2000; 113:140-5
7. Ahn DK, Chae JM, Choi HS, Kyung HM, Kwon OW, Park HS, Youn DH, Bae YC: Central cyclooxygenase inhibitors reduced IL-1beta-induced hyperalgesia in temporomandibular joint of freely moving rats. Pain 2005; 117:204-13
8. Inglis JJ, Nissim A, Lees DM, Hunt SP, Chernajovsky Y, Kidd BL: The differential contribution of tumour necrosis factor to thermal and mechanical hyperalgesia during chronic inflammation. Arthritis Res Ther 2005; 7:R807-16
9. Vissers KC, De Jongh RF, Hoffmann VL, Meert TF: Exogenous interleukin-6 increases cold allodynia in rats with a mononeuropathy. Cytokine 2005; 30:154-9
10. Kohl J: Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol Immunol 2001; 38:175-87
11. Allegretti M, Moriconi A, Beccari AR, Di Bitondo R, Bizzarri C, Bertini R, Colotta F: Targeting C5a: Recent advances in drug discovery. Curr Med Chem 2005; 12:217-36
12. Ali H, Panettieri RA Jr: Anaphylatoxin C3a receptors in asthma. Respir Res 2005; 6:19
13. Nataf S, Levison SW, Barnum SR: Expression of the anaphylatoxin C5a receptor in the oligodendrocyte lineage. Brain Res 2001; 894:321-6
14. O'Barr SA, Caguioa J, Gruol D, Perkins G, Ember JA, Hugli T, Cooper NR: Neuronal expression of a functional receptor for the C5a complement activation fragment. J Immunol 2001; 166:4154-62
15. Farkas I, Takahashi M, Fukuda A, Yamamoto N, Akatsu H, Baranyi L, Tateyama H, Yamamoto T, Okada N, Okada H: Complement C5a receptor-mediated signaling may be involved in neurodegeneration in Alzheimer's disease. J Immunol 2003; 170:5764-71
16. Boos L, Szalai AJ, Barnum SR: C3a expressed in the central nervous system protects against LPS-induced shock. Neurosci Lett 2005; 387:68-71
17. Benard M, Gonzalez BJ, Schouft MT, Falluel-Morel A, Vaudry D, Chan P, Vaudry H, Fontaine M: Characterization of C3a and C5a receptors in rat cerebellar granule neurons during maturation: Neuroprotective effect of C5a against apoptotic cell death. J Biol Chem 2004; 279:43487-96
18. Pellas TC, Wennogle LP: C5a receptor antagonists. Curr Pharm Des 1999; 5:737-55
19. Holland MC, Morikis D, Lambris JD: Synthetic small-molecule complement inhibitors. Curr Opin Investig Drugs 2004; 5:1164-73
20. Woodruff TM, Strachan AJ, Dryburgh N, Shiels IA, Reid RC, Fairlie DP, Taylor SM: Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. Arthritis Rheum 2002; 46:2476-85
21. Paczkowski NJ, Finch AM, Whitmore JB, Short AJ, Wong AK, Monk PN, Cain SA, Fairlie DP, Taylor SM: Pharmacological characterization of antagonists of the C5a receptor. Br J Pharmacol 1999; 128:1461-6
22. Strachan AJ, Shiels IA, Reid RC, Fairlie DP, Taylor SM: Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist. Br J Pharmacol 2001; 134:1778-86
23. Finch AM, Wong AK, Paczkowski NJ, Wadi SK, Craik DJ, Fairlie DP, Taylor SM: Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J Med Chem 1999; 42:1965-74
24. Pogatzki EM, Raja SN: A mouse model of incisional pain. ANESTHESIOLOGY 2003; 99:1023-7
25. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL: Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994; 53:55-63
26. Liang D, Li X, Lighthall G, Clark JD: Heme oxygenase type 2 modulates behavioral and molecular changes during chronic exposure to morphine. Neuroscience 2003; 121:999-1005
27. Liang DY, Li X, Clark JD: Formalin-induced spinal cord calcium/calmodulin-dependent protein kinase II alpha expression is modulated by heme oxygenase in mice. Neurosci Lett 2004; 360:61-4
28. Poree LR, Guo TZ, Kingery WS, Maze M: The analgesic potency of dexmedetomidine is enhanced after nerve injury: A possible role for peripheral alpha2-adrenoceptors. Anesth Analg 1998; 87:941-8
29. Guo TZ, Offley SC, Boyd EA, Jacobs CR, Kingery WS: Substance P signaling contributes to the vascular and nociceptive abnormalities observed in a tibial fracture rat model of complex regional pain syndrome type I. Pain 2004; 108:95-107
30. Li X, Clark JD: Morphine tolerance and transcription factor expression in mouse spinal cord tissue. Neurosci Lett 1999; 272:79-82
31. Woodruff TM, Pollitt S, Proctor LM, Stocks SZ, Manthey HD, Williams HM, Mahadevan IB, Shiels IA, Taylor SM: Increased potency of a novel complement factor 5a receptor antagonist in a rat model of inflammatory bowel disease. J Pharmacol Exp Ther 2005; 314:811-7
32. Marin V, Montero-Julian F, Gres S, Bongrand P, Farnarier C, Kaplanski G: Chemotactic agents induce IL-6Ralpha shedding from polymorphonuclear cells: Involvement of a metalloproteinase of the TNF-alpha-converting enzyme (TACE) type. Eur J Immunol 2002; 32:2965-70
33. Binder R, Kress A, Kirschfink M: Modulation of C5a-mediated effector functions of human polymorphonuclear leukocytes by tumor necrosis factor alpha and granulocyte macrophage colony-stimulating factor. Exp Clin Immunogenet 1999; 16:212-25
34. Gillitzer R, Goebeler M: Chemokines in cutaneous wound healing. J Leukoc Biol 2001; 69:513-21
35. Nussler AK, Wittel UA, Nussler NC, Beger HG: Leukocytes, the Janus cells in inflammatory disease. Langenbecks Arch Surg 1999; 384:222-32
36. Martin P, Leibovich SJ: Inflammatory cells during wound repair: The good, the bad and the ugly. Trends Cell Biol 2005; 15:599-607
37. Soruri A, Kim S, Kiafard Z, Zwirner J: Characterization of C5aR expression on murine myeloid and lymphoid cells by the use of a novel monoclonal antibody. Immunol Lett 2003; 88:47-52
38. Fayyazi A, Sandau R, Duong LQ, Gotze O, Radzun HJ, Schweyer S, Soruri A, Zwirner J: C5a receptor and interleukin-6 are expressed in tissue macrophages and stimulated keratinocytes but not in pulmonary and intestinal epithelial cells. Am J Pathol 1999; 154:495-501
39. Grant EP, Picarella D, Burwell T, Delaney T, Croci A, Avitahl N, Humbles AA, Gutierrez-Ramos JC, Briskin M, Gerard C, Coyle AJ: Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis. J Exp Med 2002; 196:1461-71
40. Brennan TJ, Vandermeulen EP, Gebhart GF: Characterization of a rat model of incisional pain. Pain 1996; 64:493-501
41. Li X, Clark JD: Heme oxygenase type 2 plays a role in formalin-induced nociception. Pain 2000; 86:75-80
42. Crosby G, Marota JJ, Huang PL: Intact nociception-induced neuroplasticity in transgenic mice deficient in neuronal nitric oxide synthase. Neuroscience 1995; 69:1013-7
43. Tao YX, Johns RA: Activation and up-regulation of spinal cord nitric oxide receptor, soluble guanylate cyclase, after formalin injection into the rat hind paw. Neuroscience 2002; 112:439-46
44. Tao YX, Hassan A, Haddad E, Johns RA: Expression and action of cyclic GMP-dependent protein kinase Ialpha in inflammatory hyperalgesia in rat spinal cord. Neuroscience 2000; 95:525-33
45. Shi X, Li X, Clark D: Formalin injection causes a coordinated spinal cord CO/NO-cGMP signaling system response. Mol Pain 2005; 1:33
46. Brennan TJ, Zahn PK, Pogatzki-Zahn EM: Mechanisms of incisional pain. Anesthesiol Clin North Am 2005; 23:1-20
47. Bergamaschini L, Cicardi M: Recent advances in the use of C1 inhibitor as a therapeutic agent. Mol Immunol 2003; 40:155-8
48. Ritchie BC: Protease inhibitors in the treatment of hereditary angioedema. Transfus Apher Sci 2003; 29:259-67
49. Hack CE, Voerman HJ, Eisele B, Keinecke HO, Nuijens JH, Eerenberg AJ, Ogilvie A, Strack van Schijndel RJ, Delvos U, Thijs LG: C1-esterase inhibitor substitution in sepsis (letter). Lancet 1992; 339:378
50. Hack CE, Ogilvie AC, Eisele B, Eerenberg AJ, Wagstaff J, Thijs LG: C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med 1993; 19(suppl 1):S19-28
51. Hack CE, Ogilvie AC, Eisele B, Jansen PM, Wagstaff J, Thijs LG: Initial studies on the administration of C1-esterase inhibitor to patients with septic shock or with a vascular leak syndrome induced by interleukin-2 therapy. Prog Clin Biol Res 1994; 388:335-57
52. Sato Y, Ohshima T, Kondo T: Regulatory role of endogenous interleukin-10 in cutaneous inflammatory response of murine wound healing. Biochem Biophys Res Commun 1999; 265:194-9
53. Van Der Laan N, de Leij LF, ten Duis HJ: Immunohistopathological appearance of three different types of injury in human skin. Inflamm Res 2001; 50:350-6
54. Kalff JC, Turler A, Schwarz NT, Schraut WH, Lee KK, Tweardy DJ, Billiar TR, Simmons RL, Bauer AJ: Intra-abdominal activation of a local inflammatory response within the human muscularis externa during laparotomy. Ann Surg 2003; 237:301-15
55. Zahn PK, Subieta A, Park SS, Brennan TJ: Effect of blockade of nerve growth factor and tumor necrosis factor on pain behaviors after plantar incision. J Pain 2004; 5:157-63
56. Haynes DR, Harkin DG, Bignold LP, Hutchens MJ, Taylor SM, Fairlie DP: Inhibition of C5a-induced neutrophil chemotaxis and macrophage cytokine production in vitro by a new C5a receptor antagonist. Biochem Pharmacol 2000; 60:729-33
57. Scheinfeld N: Adalimumab: A review of side effects. Expert Opin Drug Saf 2005; 4:637-41
58. Lin ZQ, Kondo T, Ishida Y, Takayasu T, Mukaida N: Essential involvement of IL-6 in the skin wound-healing process as evidenced by delayed wound healing in IL-6-deficient mice. J Leukoc Biol 2003; 73:713-21
59. Salomon GD, Kasid A, Cromack DT, Director E, Talbot TL, Sank A, Norton JA: The local effects of cachectin/tumor necrosis factor on wound healing. Ann Surg 1991; 214:175-80
60. Mooney DP, O'Reilly M, Gamelli RL: Tumor necrosis factor and wound healing. Ann Surg 1990; 211:124-9
61. Grose R, Werner S: Wound-healing studies in transgenic and knockout mice. Mol Biotechnol 2004; 28:147-66